After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $20.16 and fluctuated between $21.88 as its day high and $19.91 as its day low. The current market capitalization of Zai Lab Limited ADR is $1.99B. A total of 1.13 million shares were traded on the day, compared to an average of 670.89K shares.
In the most recent transaction, Smiley Joshua L bought 3,000 shares of ZLAB for 20.83 per share on Mar 01 ’24. After the transaction, the insider now owns 23,527 company shares. In a previous transaction on Jan 03 ’24, Du Ying sold 8,380 shares at 26.12 per share. ZLAB shares that Chairperson & CEO owns now total 1,133,450.
Among the insiders who sold shares, Edmondson Frazor Titus III disposed of 4,803 shares on Jan 03 ’24 at a per-share price of $26.12. This resulted in the Chief Legal Officer holding 30,005 shares of ZLAB after the transaction. In another insider transaction, Reinhart Harald sold 4,803 shares at $26.12 per share on Jan 03 ’24. Company shares held by the insider now total 46,060.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ZLAB has a high of $40.42 and a low of $17.68.
As of this writing, ZLAB has an earnings estimate of -$0.9 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.75 per share and a lower estimate of -$1.04. The company reported an EPS of -$0.71 in the last quarter, which was 31.70% higher than expectations of -$1.04.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ZLAB’s latest balance sheet shows that the firm has $1.41B in Cash & Short Term Investments as of fiscal 2021. There were $15.54M in debt and $192.90M in liabilities at the time. Its Book Value Per Share was $8.19, while its Total Shareholder’s Equity was $1.38B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZLAB is Buy with a score of 5.00.
